Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX- 011
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
OncoGenex Pharmaceuticals Added to Russell Indexes
OncoGenex Pharmaceuticals Files Shelf Registration Statement
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO
OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference - PR Newswire
OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference - CNW
OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study - PR Newswire
OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study - CNW
OncoGenex Reports Third Quarter Financial Results
OncoGenex Reports Third Quarter Financial Results
OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011
Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
